William Blair Reaffirms "Outperform" Rating for Exact Sciences (NASDAQ:EXAS)

Exact Sciences (NASDAQ:EXAS - Get Free Report)'s stock had its "outperform" rating reissued by equities researchers at William Blair in a report released on Monday,RTT News reports.

A number of other research firms have also weighed in on EXAS. Stifel Nicolaus lowered their target price on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Canaccord Genuity Group lowered their target price on shares of Exact Sciences from $95.00 to $75.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Evercore ISI lowered their target price on shares of Exact Sciences from $80.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. Jefferies Financial Group upped their target price on shares of Exact Sciences from $84.00 to $85.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein upped their target price on shares of Exact Sciences from $75.00 to $90.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $72.94.

Exact Sciences Stock Up 3.6 %

Shares of EXAS stock traded up $2.01 on Monday, reaching $58.51. 2,969,365 shares of the company were exchanged, compared to its average volume of 2,089,950. The company has a market cap of $10.83 billion, a price-to-earnings ratio of -50.01 and a beta of 1.24. The company has a 50-day moving average of $57.82 and a 200-day moving average of $58.88. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. Exact Sciences has a one year low of $40.62 and a one year high of $79.62.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company had revenue of $708.66 million for the quarter, compared to the consensus estimate of $716.80 million. Exact Sciences's revenue was up 12.8% on a year-over-year basis. Analysts anticipate that Exact Sciences will post -1.13 earnings per share for the current year.

Insider Transactions at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy acquired 19,500 shares of the business's stock in a transaction that occurred on Wednesday, November 13th. The stock was bought at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the acquisition, the chief executive officer now owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. This represents a 1.85 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.36% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of EXAS. Groupama Asset Managment bought a new position in Exact Sciences in the 3rd quarter worth approximately $821,000. Sculptor Capital LP bought a new position in Exact Sciences in the 2nd quarter valued at $32,819,000. Samlyn Capital LLC bought a new position in Exact Sciences in the 2nd quarter valued at $30,426,000. Armistice Capital LLC boosted its holdings in Exact Sciences by 91.6% in the 2nd quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company's stock valued at $59,154,000 after purchasing an additional 669,438 shares during the period. Finally, ArrowMark Colorado Holdings LLC bought a new position in Exact Sciences in the 3rd quarter valued at $28,608,000. 88.82% of the stock is owned by institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.